Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

Or was it 1974? By Laurie Gwen Shapiro One morning in the mid-1970s, a solemn announcement came over the intercom at Friends Seminary: “Noted person John Lennon is now in the meetinghouse.

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

AAA-614 is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

TIN-816 is under clinical development by Novartis and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs for Sepsis have a 50% phase transition success rate (PTSR) indication ...

including chief medical officer John Tsai who is leaving the company on 15 May, four years after joining from Amgen. Head of Novartis oncology Susanne Schaffert also has no place in the new ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...